In vivo imaging of astrocytosis in Alzheimer’s disease: an 11C-L-deuteriodeprenyl and PIB PET study

  • Alexander Frizell Santillo
  • Juan Pablo Gambini
  • Lars Lannfelt
  • Bengt Långström
  • Luohija Ulla-Marja
  • Lena Kilander
  • Henry Engler
Original Article

Abstract

Purpose

Astrocytosis is an important feature of the neuropathology of Alzheimer’s disease (AD), yet there is currently no way of detecting this phenomenon in vivo.

Methods

In this study we examine the retention of the positron emission tomography (PET) tracer 11C-L-deuteriodeprenyl (DED), thought to bind activated astrocytes, in 9 patients with moderate to severe AD compared with 11 healthy controls. As a measure of amyloid load, 11C-labelled Pittsburgh Compound B (PIB) retention was determined.

Results

Results show a significantly higher 11C-L-DED retention in the frontal (35.1% increase, p = 0.001), parietal (35.2%, p = 0.001), temporal (30.9%, p = 0.0001) and medial temporal lobes (22.3%, p = 0.001) in AD compared to healthy controls after blood flow correction. DED retention in the sensorimotor and occipital cortices, and in white matter and subcortical structures, did not differ between groups. There was a moderate but statistically significant (r = 0.492, p = 0.01) correlation between DED and PIB retention values.

Conclusion

Our conclusion is that DED may serve as an in vivo marker for astrocytosis in AD, providing a window into intermediate processes between amyloidosis and neuronal loss and a means of monitoring immunotherapy.

Keywords

11C-L-deuteriodeprenyl Pittsburgh Compound B Astrocytosis Alzheimer’s disease Positron emission tomography 

References

  1. 1.
    Rodríguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer’s disease. Cell Death Differ 2009;16(3):378–85.PubMedGoogle Scholar
  2. 2.
    Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009;66(1):60–7.PubMedGoogle Scholar
  3. 3.
    Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358(9280):461–7.PubMedGoogle Scholar
  4. 4.
    Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 1990;80:419–25.PubMedGoogle Scholar
  5. 5.
    Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 1994;62:15–30.PubMedGoogle Scholar
  6. 6.
    Wisniewski HM, Wegiel J. Spatial relationships between astrocytes and classical plaque components. Neurobiol Aging 1991;12:593–600.PubMedGoogle Scholar
  7. 7.
    Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease. Neurobiol Aging 2004;25:663–74.PubMedGoogle Scholar
  8. 8.
    Ekblom J, Jossan SS, Bergström M, Oreland L, Walum E, Aquilonius SM. Monoamine oxidase-B in astrocytes. Glia 1993;8(2):122–32.PubMedGoogle Scholar
  9. 9.
    Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A 1982;79(20):6385–9.PubMedGoogle Scholar
  10. 10.
    Jossan SS, d’Argy R, Gillberg PG, Aquilonius SM, Långström B, Halldin C, et al. Localization of monoamine oxidase B in human brain by autoradiographical use of 11C-labelled L-deprenyl. J Neural Transm 1989;77:55–64.PubMedGoogle Scholar
  11. 11.
    Jossan SS, Gillberg PG, Giotfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer’s disease: a biochemical and autoradiographical study. Neuroscience 1991;45(1):1–12.PubMedGoogle Scholar
  12. 12.
    Fowler CJ, Wiberg A, Oreland L, Marcusson J, Winblad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 1980;49:1–20.PubMedGoogle Scholar
  13. 13.
    Freedman NM, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med 2005;46(10):1618–24.PubMedGoogle Scholar
  14. 14.
    Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther 2009;85(5):506–12. Epub 2009 Jan 7.PubMedGoogle Scholar
  15. 15.
    Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987;235(4787):481–5.PubMedGoogle Scholar
  16. 16.
    Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995;36(7):1255–62.PubMedGoogle Scholar
  17. 17.
    Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius SM, et al. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci 2007;255(1–2):17–22. Epub 2007 Mar 7.PubMedGoogle Scholar
  18. 18.
    Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergström M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging 2003;30(1):85–95.PubMedGoogle Scholar
  19. 19.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306–19.PubMedGoogle Scholar
  20. 20.
    Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease. Brain 2011;134:301–17.PubMedGoogle Scholar
  21. 21.
    Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129(Pt 11):2856–66. Epub 2006 Jul 19.PubMedGoogle Scholar
  22. 22.
    Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29(10):1456–65. Epub 2007 May 11.PubMedGoogle Scholar
  23. 23.
    Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43(2):250–60.PubMedGoogle Scholar
  24. 24.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedGoogle Scholar
  25. 25.
    McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 Suppl):417–23.PubMedGoogle Scholar
  26. 26.
    Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–54.PubMedGoogle Scholar
  27. 27.
    Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, et al. Mechanistic positron emission tomography studies: demonstration of deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain. J Neurochem 1988;51:1524–34.PubMedGoogle Scholar
  28. 28.
    MacGregor RR, Fowler JS, Wolf AP, Halldin C, Langström B. Synthesis of suicide inhibitors of monoamine oxidase: carbon-11 labeled clorgyline, L-deprenyl and D-deprenyl. J Labelled Comp Radiopharm 1988;25:1–9.Google Scholar
  29. 29.
    Bergström M, Kumlien E, Lilja A, Tyrefors N, Westerberg G, Långström B. Temporal lobe epilepsy visualized with PET with 11C-L-deuterium-deprenyl—analysis of kinetic data. Acta Neurol Scand 1998;98:224–31.PubMedGoogle Scholar
  30. 30.
    Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–72.PubMedGoogle Scholar
  31. 31.
    Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A, Forsberg A, et al. Unidirectional influx and net accumulation of PIB. Open Neuroimag J 2008;2:114–25.PubMedGoogle Scholar
  32. 32.
    Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med 2011;52(2):173–9. Epub 2011 Jan 13.PubMedGoogle Scholar
  33. 33.
    Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increase in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997;18(4):431–5.PubMedGoogle Scholar
  34. 34.
    Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer’s and Parkinson’s diseases. Prog Brain Res 1998;117:267–85.PubMedGoogle Scholar
  35. 35.
    Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer’s disease related cortical lesions. J Neural Transm Suppl 1998;54:97–106.PubMedGoogle Scholar
  36. 36.
    Nelson P, Jicha G, Schmitt F, Liu H, Davis D, Mendiondo M, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol 2007;66:1136–46.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Alexander Frizell Santillo
    • 1
    • 2
  • Juan Pablo Gambini
    • 3
    • 7
  • Lars Lannfelt
    • 2
  • Bengt Långström
    • 4
  • Luohija Ulla-Marja
    • 5
    • 6
  • Lena Kilander
    • 2
  • Henry Engler
    • 3
    • 7
  1. 1.Geriatric Psychiatry, Department of Clinical MedicineLund UniversityLundSweden
  2. 2.Department of Public Health and Caring Sciences/GeriatricsUppsala UniversityUppsalaSweden
  3. 3.Faculty of Medicine and Faculty of ScienceUniversity of the RepublicMontevideoUruguay
  4. 4.Departments of Biochemistry and Organic ChemistryUppsala UniversityUppsalaSweden
  5. 5.Helsinki University HospitalHelsinkiFinland
  6. 6.Department of Medical Sciences, Clinical PhysiologyUppsala UniversityUppsalaSweden
  7. 7.Uruguayan Centre of Molecular Imaging (CUDIM)MontevideoUruguay

Personalised recommendations